Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Kristen W Cohen

Fred Hutchinson Cancer Research Center

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

80%

Virology

80%

Hiv

70%

Vaccine Development

30%

T Cell Biology

30%

Immunotherapy

30%

Vaccinology

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles12

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial

Article Link

Year:

2025

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming

Article Link

Year:

2024

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

Article Link

Year:

2023

Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1–uninfected adult participants in the US

Article Link

Year:

2023

Persistent serum protein signatures define an inflammatory subcategory of long COVID

Article Link

Year:

2023

A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses

Article Link

Year:

2023

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Article Link

Year:

2022

Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4+ T Cells That Correlated with Reduced Risk of Infection in RV144 Trial

Article Link

Year:

2022

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

Article Link

Year:

2022

Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial

Article Link

Year:

2021

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection

Article Link

Year:

2021

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

Article Link

Year:

2020

Collaborators13

Nicole Grunenberg

Fred Hutchinson Cancer Research Center

UNITED STATES

Kathryn Stephenson

Assistant Professor of Medicine

Beth Israel Deaconess Medical Center

UNITED STATES

Andrew Fiore-Gartland

Fred Hutchinson Cancer Research Center

UNITED STATES

Martin Corcoran

Karolinska Institutet

SWEDEN

Jesse Clark

Associate Professor-in-Residence

David Geffen School of Medicine at UCLA

UNITED STATES

Kenneth Mayer

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES

Kristin Ladell

Clinical Reader & Doctor in Paediatrics

Cardiff University

UNITED KINGDOM

Stephen Walsh

Assistant Professor

Brigham and Women's Hospital

UNITED STATES

Margaret. Juliana McElrath

Director, Professor and Senior Vice President

Fred Hutchinson Cancer Research Center

UNITED STATES

Allan deCamp

Fred Hutchinson Cancer Research Center

UNITED STATES

Raphael Gottardo

University of Lausanne

SWITZERLAND

Paul Goepfert

The University of Alabama

UNITED STATES

Matthew Gray

Fred Hutchinson Cancer Research Center

UNITED STATES

How do I reach out?

Meet Kite AI